|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Qiu ZL, Shen CT, Sun ZK, Wei WJ, Zhang XY,
Song HJ and Luo QY: Circulating long non-coding RNAs act as
biomarkers for predicting 131I uptake and mortality in papillary
thyroid cancer patients with lung metastases. Cell Physiol Biochem.
40:1377–1390. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pfeifer GP, Denissenko MF, Olivier M,
Tretyakova N, Hecht SS and Hainaut P: Tobacco smoke carcinogens,
DNA damage and p53 mutations in smoking-associated cancers.
Oncogene. 21:7435–7451. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang H and Cai B: The impact of tobacco
on lung health in China. Respirology. 8:17–21. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Furrukh M: Tobacco smoking and lung
cancer: Perception-changing facts. Sultan Qaboos Univ Med J.
13:345–358. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Owonikoko TK, Ragin CC, Belani CP, Oton
AB, Gooding WE, Taioli E and Ramalingam SS: Lung cancer in elderly
patients: An analysis of the surveillance, epidemiology, and end
results database. J Clin Oncol. 25:5570–5577. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Finn OJ: Immuno-oncology: Understanding
the function and dysfunction of the immune system in cancer. Ann
Oncol. 23 Suppl 8:viii6–viii9. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Takeda M, Okamoto I, Sakai K, Kawakami H,
Nishio K and Nakagawa K: Clinical outcome for EML4-ALK-positive
patients with advanced non-small-cell lung cancer treated with
first-line platinum-based chemotherapy. Ann Oncol. 23:2931–2936.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Janku F, Garrido-Laguna I, Petruzelka LB,
Stewart DJ and Kurzrock R: Novel therapeutic targets in non-small
cell lung cancer. J Thorac Oncol. 6:1601–1612. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Minguet J, Smith KH and Bramlage P:
Targeted therapies for treatment of non-small cell lung
cancer-Recent advances and future perspectives. Int J Cancer.
138:2549–2561. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Silvestri GA, Gould MK, Margolis ML,
Tanoue LT, McCrory D, Toloza E and Detterbeck F: American College
of Chest Physicians: Noninvasive staging of non-small cell lung
cancer. ACCP evidenced-based clinical practice guidelines (2nd
edition) Chest. 132 (3 Suppl):S178–S201. 2007.
|
|
13
|
Gould MK, Kuschner WG, Rydzak CE, Maclean
CC, Demas AN, Shigemitsu H, Chan JK and Owens DK: Test performance
of positron emission tomography and computed tomography for
mediastinal staging in patients with non-small-cell lung cancer: A
meta-analysis. Ann Intern Med. 139:879–892. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis
CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D and de Vet
HC: Standards for Reporting of Diagnostic Accuracy: Towards
complete and accurate reporting of studies of diagnostic accuracy:
The STARD initiative. Radiology. 226:24–28. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bille A, Pelosi E, Skanjeti A, Arena V,
Errico L, Borasio P, Mancini M and Ardissone F: Preoperative
intrathoracic lymph node staging in patients with non-small-cell
lung cancer: Accuracy of integrated positron emission tomography
and computed tomography. Eur J Cardiothorac Surg. 36:440–445. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kong E, Peng S, Chandra G, Sarkar C, Zhang
Z, Bagh MB and Mukherjee AB: Dynamic palmitoylation links
cytosol-membrane shuttling of Acyl-protein thioesterase-1 and
Acyl-protein thioesterase-2 with that of proto-oncogene H-ras
product and growth-associated protein-43. J Biol Chem.
288:9112–9125. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Berg V, Rusch M, Vartak N, Jüngst C,
Schauss A, Waldmann H, Hedberg C, Pallasch CP, Bastiaens PI, Hallek
M, et al: miRs-138 and −424 control palmitoylation-dependent
CD95-mediated cell death by targeting acyl protein thioesterases 1
and 2 in CLL. Blood. 125:2948–2957. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Magee AI and Courtneidge SA: Two classes
of fatty acid acylated proteins exist in eukaryotic cells. EMBO J.
4:1137–1144. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Magee AI, Gutierrez L, McKay IA, Marshall
CJ and Hall A: Dynamic fatty acylation of p21N-ras. EMBO J.
6:3353–3357. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Martin BR, Wang C, Adibekian A, Tully SE
and Cravatt BF: Global profiling of dynamic protein palmitoylation.
Nat Methods. 9:84–89. 2012. View Article : Google Scholar
|
|
21
|
Duncan JA and Gilman AG: A cytoplasmic
acyl-protein thioesterase that removes palmitate from G protein
alpha subunits and p21(RAS). J Biol Chem. 273:15830–15837. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Smotrys JE and Linder ME: Palmitoylation
of intracellular signaling proteins: Regulation and function. Annu
Rev Biochem. 73:559–587. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sato G: Tissue culture: The unrealized
potential. Cytotechnology. 57:111–114. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Stratton MR, Campbell PJ and Futreal PA:
The cancer genome. Nature. 458:719–724. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wistuba II, Bryant D, Behrens C, Milchgrub
S, Virmani AK, Ashfaq R, Minna JD and Gazdar AF: Comparison of
features of human lung cancer cell lines and their corresponding
tumors. Clin Cancer Res. 5:991–1000. 1999.PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Linder ME and Deschenes RJ:
Palmitoylation: Policing protein stability and traffic. Nat Rev Mol
Cell Biol. 8:74–84. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bijlmakers MJ and Marsh M: The on-off
story of protein palmitoylation. Trends Cell Biol. 13:32–42. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Resh MD: Palmitoylation of ligands
receptors and intracellular signaling molecules. Sci STKE.
2006:re142006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Salaun C, Greaves J and Chamberlain LH:
Intracellular dynamic of protein palmitoylation. J Cell Biol.
191:1229–1238. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hellsten E, Vesa J, Olkkonen VM, Jalanko A
and Peltonen L: Human palmitoyl protein thioesterase: Evidence for
lysosomal targeting of the enzyme and disturbed cellular routing in
infantile neuronal ceroid lipofuscinosis. EMBO J. 15:5240–5245.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chang A: Chemotherapy, chemoresistance and
the changing treatment landscape for NSCLC. Lung Cancer. 71:3–10.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Willers H, Azzoli CG, Santivasi WL and Xia
F: Basic mechanisms of therapeutic resistance to radiation and
chemotherapy in lung cancer. Cancer J. 19:200–207. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xie D, Lan L, Huang K, Chen L, Xu C, Wang
R, Shi Y, Wu X, Wang L, Liu Y and Lu B: Association of p53/p21
expression and cigarette smoking with tumor progression and poor
prognosis in non-small cell lung cancer patients. Oncol Rep.
32:2517–2526. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lee EY and Muller WJ: Oncogenes and tumor
suppressor genes. Cold Spring Harb Perspect Biol. 2:a0032362010.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lee KW, Kim JH, Han S, Sung CO, Do IG, Ko
YH, Um SH and Kim SH: Twist1 is an independent prognostic factor of
esophageal squamous cell carcinoma and associated with its
epithelial-mesenchymal transition. Ann Surg Oncol. 19:326–335.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yi ZY, Feng LJ, Xiang Z and Yao H:
Vascular endothelial growth factor receptor-1 activation mediates
epithelial to mesenchymal transition in hepatocellular carcinoma
cells. J Invest Surg. 24:67–76. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xu X, Zhu Y, Liang Z, Li S, Xu X, Wang X,
Wu J, Hu Z, Meng S, Liu B, et al: c-Met and CREB1 are involved in
miR-433-mediated inhibition of the epithelial-mesenchymal
transition in bladder cancer by regulating Akt/GSK-3β/Snail
signaling. Cell Death Dis. 7:e20882016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Miettinen PJ, Ebner R, Lopez AR and
Derynck R: TGF-beta induced transdifferentiation of mammary
epithelial cells to mesenchymal cells: Involvement of type I
receptors. J Cell Biol. 127:2021–2036. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bucay N, Bhagirath D, Sekhon K, Yang T,
Fukuhara S, Majid S, Shahryari V, Tabatabai Z, Greene KL, Hashimoto
Y, et al: A novel microRNA regulator of prostate cancer
epithelial-mesenchymal transition. Cell Death Differ. 24:1263–1274.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Qiao Y, Jiang X, Lee ST, Karuturi RK, Hooi
SC and Yu Q: FOXQ1 regulates epithelial-mesenchymal transition in
human cancers. Cancer Res. 71:3076–3086. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Van Roy F and Berx G: The cell-cell
adhesion molecule E-cadherin. Cell Mol Life Sci. 65:3756–3788.
2008. View Article : Google Scholar : PubMed/NCBI
|
